[(177)Lu-PSMA therapy : Current evidence for use in the treatment of patients with metastatic prostate cancer]

Despite significant progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC) in recent years (including agents targeting androgen receptor signaling, chemotherapy, and (223)Ra), most of these patients still succumb to prostate cancer. Recently, (177)lutetium prostate-specific membrane antigen radioligand therapy ((177)Lu-PSMA-RLT) has been increasingly used within compassionate use provisions in these patients in Germany and showed promising efficacy.

Establishment of the current position of (177)Lu-PSMA-RLT in mCRPC in 2017.

Presentation of the therapy landscape in mCRPC and the current challenges within treatment and survey of the available data on (177)Lu-PSMA-RLT after PubMed-based research.

In several larger retrospective studies, (177)Lu-PSMA-RLT seems to be an encouraging new option with the potential to extend overall survival while displaying a favorable toxicity profile.

Prospective trials are urgently needed to confirm these encouraging results found in retrospective analyses with (177)Lu-PSMA-RLT in the treatment of mCRPC.

Der Urologe. Ausg. A. 2017 Oct 06 [Epub ahead of print]

M Boegemann, A J Schrader, K Rahbar

Klinik für Urologie und Kinderurologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1 GB A1, 48149, Münster, Deutschland. ., Klinik für Urologie und Kinderurologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1 GB A1, 48149, Münster, Deutschland., Klinik für Nuklearmedizin, Universitätsklinikum Münster, Münster, Deutschland.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe